-- Dr.
-- First in a series of planned webcasts hosted by Blueprint to highlight evolving science around R&D and pipeline strategy --
Mast cells are increasingly implicated in the pathogenesis of a wide range of allergic and inflammatory conditions, leading to an acceleration in research into mast cell biology. This webcast will focus on the biology of mast cells, including their essential role as drivers of and contributors to inflammatory responses, their core involvement in biological pathways relevant to an array of allergic and inflammatory diseases, and Blueprint's approach to modulating mast cells and building a pipeline in allergic and inflammatory disease. The webcast will include a presentation and live Q&A.
The powerful mast cell: a promising target for treating allergic and inflammatory diseases
Date: Thursday, April 25, 2024
Time: 10:00 a.m. ET
Presenters:
Guest speaker
Mariana Castells , M.D., Ph.D., Director, Mastocytosis Center at Brigham and Women's Hospital
Blueprint Medicines speakers
- Fouad Namouni, M.D., President, Research & Development
Becker Hewes , M.D., Chief Medical OfficerPercy H. Carter , Ph.D., MBA, Chief Scientific Officer
To access the live webcast, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 814168. A live webcast of the event will be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after each event and will be available thereafter.
Blueprint plans to host the next webcast in the series in the second half of 2024.
About Blueprint Medicines
Blueprint Medicines is a fully integrated, commercial-stage, global biopharmaceutical company that invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. We pursue discovery, development, and commercialization of therapies that potently and selectively target known drivers of disease, with focused investment in therapeutic areas where we can leverage our core expertise and business infrastructure to bring scale to our science. We are bringing AYVAKIT ®/AYVAKYT ® (avapritinib) to people living with systemic mastocytosis (SM) in the